Iconovo has moved into new labs and offices at Medicon Village. We have now doubled our space and have several specialized labs and equipment for dry powder formulation development and analytical work. We have also invested in climate cabinets to be able to perform stability studies.

Iconovo has raised 2.3 million EUR to expand the in-house development capacity. We will now be able to offer a comprehensive product development including device, formulation and analytical testing.

Iconovo CEO Dr. Orest Lastow will be giving a speach at Dry Powder Inhalers Conference 27-28 July in London. The title of the speach is “How to develop a generic DPI: from scratch to market”. Download programme here.

Iconovo will be joining RDD Europe 2017 in Nice next week. Iconovo’s participation was made possible by the kind support from the EU financed SSGG project

We welcome our two new associates: Richard Johnson and Fredrik Gunnarsson. Richard is a Mechanical Engineer and Fredrik is an Analytical Chemist.

Iconovo was a Bronze sponsor of DDL in Edinburgh. The sponsorship was in cooperation with EU financed SSGG project.

Dr Mikael Arinder is Iconovo’s new Vice President Operations. Mikael has a PhD. in organic chemistry and has long experience from the pharmaceutical industry and particularly from the respiratory area. Mikael was with AstraZeneca for 14 years and had many senior roles. He now joins us from McNeal where he was Associate Director of Analytical Development. Mikael will be responsible for Iconovo’s customer projects.

Iconovo has signed an agreement for a licensing deal and a product development project with Amneal Pharmaceuticals that produce and market generic drug products. The agreement involves an adaptation of Iconovo’s unique inhaler, ICOres™ as well as a development of a powder formulation to treat asthma and COPD. Iconovo will receive an up-front payment and milestone payments in the mid-single digit Euro millions range during development through regulatory approvals and royalties after commercial launch.

Iconovo has received a 350 000 USD grant from Sweden’s innovation agency Vinnova. The development project includes optimization of ICOone and adaptation for high-volume low-cost commercial manufacturing. ICOone is primary intended for inhaled vaccines but is also suitable for biomolecules and high cost drugs.

Iconovo has signed a development agreement with Copenhagen University. Iconovo’s unit-dose inhaler ICOone will be used in two PhD projects investigating novel drug formulations at Faculty of Health and Medical Sciences. ICOone is the perfect test device when developing either traditional drug formulations or novel engineered drug formulations.